Update on strategies to improve thrombolysis for acute myocardial infarction

Pharmacotherapy

Volumn 21, Issue 6, 2001, Pages 691-716

  Spinler, Sarah A ^a,b   Inverso, Stephanie M ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEMENTIN; HEPARIN; HIRULOG; LAMIFIBAN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR; RECOMBINANT THROMBIN ACTIVATED PLASMINOGEN; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BIOEQUIVALENCE; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY STENT; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; EMERGENCY TREATMENT; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE;

ANGIOPLASTY, BALLOON; ANTIBODIES, MONOCLONAL; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RESCUE WORK; THROMBOLYTIC THERAPY;

EID: 0034982169     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.7.691.34579     Document Type: Review

References (114)

1. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
2. Link between the angiographic sub-study and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion
3. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge
4. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
5. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries trial. Extended mortality benefit of early postinfarction reperfusion
6. Primary stenting and glycoprotein IIb-IIIa inhibitors in acute myocardial infarction
7. Combination therapy for acute myocardial infarction: Glycoprotein IIb-IIIa inhibitors plus thrombolysis
8. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction
9. Conjunctive use of platelet glycoprotein IIb-IIIa antagonists and thrombolytic therapy for acute myocardial infarction
10. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
11. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
12. Molecular biology of plasminogen activators: What are the clinical implications of drug design?
13. New plasminogen activators: A clinical review
14. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model
15. A fresh look at the molecular pharmacology of plasminogen activators: From theory to test tube to clinical outcomes
16. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase, and urokinase in a canine model of coronary artery thrombosis
17. Comparative thrombolytic properties of tissue-type plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
18. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding
19. A faster-acting and more potent form of tissue plasminogen activator
20. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
21. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
22. Open noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction
23. BM 06.022: A novel recombinant plasminogen activator
24. Current status of thrombolytic drug development
25. Prehospital-initiated thrombolysis
26. Duration of, and temporal trends (1994-1997) in, prehospital delay in patients with acute myocardial infarction: The second national registry of myocardial infarction
27. Factors influencing the time to thrombolysis in acute myocardial infarction
28. Delay between onset of chest pain and seeking medical care: The effect of public education
29. "Call fast, call 911": A direct mail campaign to reduce patient delay in acute myocardial infarction
30. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. From 1990 through 1999
31. 1999 update: ACC/AHA guidelines for management of patients with acute myocardial infarction: Executive summary and recommendations: A report from the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Management of Acute Myocardial Infarction)
32. Primary angioplasty versus thrombolysis for acute myocardial infarction
33. Update: Enhanced prehospital response to acute myocardial infarction
34. Pre-hospital thrombolysis: An idea whose time has come
35. Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the national registry of myocardial infarction 2
36. Randomised, double-blind comparison to reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence
37. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
38. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in acute myocardial infarction
39. A comparison of reteplase with alteplase for acute myocardial infarction
40. TIMI grade flow, mortality, and the GUSTO-III trial
41. Equivalence trials
42. Thrombolytic therapy for myocardial infarction
43. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA
44. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial
45. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
46. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
47. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
48. Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction
49. Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction
50. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase
51. Results from late-breaking clinical trial sessions at ACCIS '99 and ACC '99
52. Highlights of the 48th scientific sessions of the American College of Cardiology
53. Long-term comparison of lanoteplase and alteplase in ST elevation myocardial infarction: 6 month follow-up in In-TIME-II trial
54. In TIMI-2b: Omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase
55. Outcome of attempted rescue coronary angioplasty after failed thrombolysis for acute myocardial infarction. Cohort of rescue angioplasty in myocardial infarction
56. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
57. Clinical cardiology: New frontiers: Thrombolysis for acute myocardial infarction
58. Failed coronary thrombolysis
59. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity
60. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
61. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. Global use of strategies to open occluded coronary arteries
62. ST-segment resolution and infarct-related patency and flow after thrombolytic therapy
63. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction
64. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator: Results of the thrombolysis in myocardial infarction (TIMI) phase II-A trial
65. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty
66. The thrombolysis in myocardial infarction (TIMI) trial phase II: Additional information and perspectives
67. Rescue angioplasty during myocardial infarction has a beneficial effect on mortality: A tenable hypothesis
68. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction
69. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: Insight from RESCUE I, RESCUE II, and other contemporary experiences
70. Coronary angioplasty with or without stent implantation for acute myocardial infarction
71. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial)
72. Effectiveness and safety of abciximab after failed thrombolytic therapy
73. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: Results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial
74. Rescue thrombolysis: Alteplase as adjuvant treatment after streptokinase in acute myocardial infarction
75. Efficacy of rescue thrombolysis in patients with acute myocardial infarction: Preliminary findings
76. A clinical trial comparing primary PICA with tissue plasminogen activator for acute myocardial infarction
77. IIb-IIIa receptor blockade in acute myocardial infarction
78. Combination therapy for acute myocardial infarction: Glycoprotein IIb-IIIa inhibitors plus thrombolysis
79. 2 receptors: With a review of platelet-leukocyte interactions
80. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study
81. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb-IIIa integrilin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
82. Combined therapy with streptokinase and integrilin
83. Combining thrombolysis with the platelet glycoprotein IIb-IIIa Inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial
84. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
85. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
86. INTRO AMI: Marked enhancement of arterial patency with eptifibatide and low dose t-PA in acute myocardial infarction
87. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty
88. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
89. Effect of early intravenous heparin on coronary artery patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European cooperative study group trial
90. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial
91. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
92. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial
93. Comparative effects of low molecular weight heparin (with and without abciximab) and unfractionated heparin on antithrombin activity during coronary angioplasty
94. Differential effects of anticoagulants on the activation of platelets ex vivo
95. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin
96. Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction: A dose finding study
97. Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: A dose-finding study
98. Enoxaparin vs. Unfractionated heparin as adjunctive therapy to rt-PA in acute myocardial infarction: Results of the heparins and reperfusion trial II (HART II) pilot study
99. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - A pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II)
100. Low molecular weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction
101. Myocardial ischemia and infarction
102. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty
103. A randomized trial of immediate versus delayed angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
104. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: The TIMI II-A results
105. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty of acute myocardial infarction
106. Triple therapy for acute myocardial infarction: Combining fibrinolysis, platelet IIb-IIIa inhibition, and percutaneous coronary intervention
107. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial
108. Platelet glycoprotein IIb-IIIa receptor blockade in coronary artery disease
109. Abciximab improves both epicardial flow and endocardial reperfusion in ST elevation MI: A TIMI 14 analysis
110. Combination abciximab and reduced-dose reteplase facilitates early PCI in myocardial infarction: Results from the SPEED trial
111. Favorable results with immediate coronary intervention after low dose t-PA and eptifibatide for AMI: Results from the INTRO-AMI trial
112. IIb-IIIa receptor antagonists for failed rescue angioplasty
113. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty